Loading organizations...
Precision medicine through advanced blood analysis for tailored therapies.
Precede Biosciences develops a liquid biopsy platform providing high-resolution insights into disease biology. This technology profiles circulating chromatin and the DNA methylome from a blood sample, elucidating dynamic gene and pathway activation. The platform utilizes molecular techniques and proprietary machine learning to uncover the activation status of therapeutically actionable genes.
The company was co-founded in 2021 by Rehan Verjee, who also serves as Chief Executive Officer. The core insight for Precede Biosciences stemmed from the understanding that comprehensive epigenomic information, derived from a simple blood test, could significantly advance precision medicine by revealing dynamic biological states crucial for treatment.
Precede Biosciences partners with pharmaceutical developers and progresses its own diagnostic tests. Its vision is to improve new medicine development success and ensure patients receive minimally invasive diagnoses and treatments precisely tailored to the unique biological characteristics of their specific disease.
Precede Biosciences has raised $140.5M across 2 funding rounds.
Precede Biosciences has raised $140.5M in total across 2 funding rounds.
Precede Biosciences is a clinical-stage technology company building a first‑in‑class, epigenomics-based liquid biopsy platform that profiles disease-defining transcriptional biology from a small blood draw to inform drug development and precision cancer diagnostics[1][2].
High-Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
If you’d like, I can: summarize recent peer‑reviewed data supporting circulating chromatin/methylome profiling, map Precede’s investor and partnership landscape in more detail, or draft a one‑page investor brief based on the above.
Precede Biosciences has raised $140.5M in total across 2 funding rounds.
Precede Biosciences's investors include 5AM Ventures, Alexandria Venture Investments, Binney Street Capital, Bristol Myers Squibb, Wouter Meuleman, Labcorp, Lilly Asia Ventures, Mirae Asset Capital, Osage University Partners, Tiger Gene, Matthias Kleinz, Ed Mathers.
Precede Biosciences has raised $140.5M across 2 funding rounds. Most recently, it raised $83.5M Debt / Series B in January 2026.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 12, 2026 | $83.5M Debt / Series B | 5AM Ventures, Alexandria Venture Investments, Binney Street Capital, Bristol Myers Squibb, Wouter Meuleman, Labcorp, Lilly Asia Ventures, Mirae Asset Capital, Osage University Partners, Tiger Gene, Matthias Kleinz | |
| Oct 1, 2023 | $57.0M Series A | 5AM Ventures, Ed Mathers, Heather Preston |